Estrogen is predominant in the development of breast cancer, and efforts are under way to develop effective therapies targeting estrogen signaling. The result of the July 2003 Gleneagles Conference, these papers and transcripts of panel discussions evaluate the clinical pharmacology of selective estrogen receptor modulators (SERMs), selective estro